Resumo

MACEDO, Olinda et al. Profile of secondary genotypic resistance to antiretroviral drugs in aids patients in the States of Pará and Amazonas, Brazil: 2002 to 2006. Rev Pan-Amaz Saude [online]. 2011, vol.2, n.3, pp.27-34. ISSN 2176-6215.  http://dx.doi.org/10.5123/S2176-62232011000300004.

Resistance to antiretroviral drugs results from the incomplete suppression of HIV-1 replication. The present study characterized the profile of genotypic resistance to antiretroviral drugs (ARVs) in serum samples from 127 HIV-positive patients from the States of Amazonas and Pará, in Northern Brazil, from 2002 to 2006. The samples were tested for resistance using the ViroSeq^TM Genotyping System kit. Based on the genetic information obtained from the HIV-1 protease (PR) and/or reverse transcriptase (RT) genes, the M184V mutation (81.1%) was the most frequently associated with resistance to nucleoside reverse transcriptase inhibitors (NRTIs) in individuals using ARVs in Pará, while the T215F/Y mutation (56.3%) was the most frequently associated with resistance in individuals from Amazonas. The K103N mutation was the most prevalent (33.5%) resistance mutation to non-nucleoside reverse transcriptase inhibitors (NNRTIs) in both states. For the PR gene, the minor mutation L63P (65.3%) was the most frequent in both states. The present study showed the importance of identifying mutations associated with resistance to ARVs to the rational selection of therapeutic schemes. Additionally, the results found in Pará and Amazonas were found to be similar to those of other areas in Brazil.

Palavras-chave : Terapia Anti-Retroviral; VIH-1; Mutation; Genotyping.

        · resumo em Português | Espanhol     · texto em Português | Espanhol     · Português ( pdf ) | Espanhol ( pdf )